Exclusive enteral nutrition – first-line therapy of Crohn’s disease in children

2015 ◽  
Vol 69 (6) ◽  
pp. 531-535
Author(s):  
Eva Karásková
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Enteral Nutrition ◽  
First Line ◽  
Exclusive Enteral Nutrition ◽  
First Line Therapy ◽  
Line Therapy ◽  
Therapy Of Crohn's Disease

Exclusive enteral nutrition continues to be first line therapy for pediatric Crohn's disease in the era of biologics

2015 ◽  
Vol 83 (1) ◽  
pp. 47-54
Author(s):  
V.M. Navas-López ◽  
J. Blasco-Alonso ◽  
S. Lacasa Maseri ◽  
F. Girón Fernández-Crehuet ◽  
M.J. Serrano Nieto ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Enteral Nutrition ◽  
First Line ◽  
Exclusive Enteral Nutrition ◽  
First Line Therapy ◽  
Line Therapy

Efficacy of adalimumab as first-line therapy in pediatric Crohn's disease

2017 ◽  
Vol 49 (4) ◽  
pp. e261
Author(s):  
L. Zenzeri ◽  
B. Pigneur ◽  
L. Norsa ◽  
E. Farinelli ◽  
S. Esposito ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?

2013 ◽  
Vol 10 (6) ◽  
pp. 345-351 ◽  
Author(s):  
Laurent Peyrin-Biroulet ◽  
Gionata Fiorino ◽  
Anthony Buisson ◽  
Silvio Danese
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals Management of Crohn's disease

2015 ◽  
Vol 101 (5) ◽  
pp. 475-480 ◽  
Author(s):  
Jochen Kammermeier ◽  
Mary-Anne Morris ◽  
Vikki Garrick ◽  
Mark Furman ◽  
Astor Rodrigues ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Enteral Nutrition ◽  
Line Treatment ◽  
First Line ◽  
Exclusive Enteral Nutrition ◽  
Immunosuppressant Treatment ◽  
Active Disease ◽  
First Line Treatment

Crohn's disease (CD) is rapidly increasing in children so an up to date knowledge of diagnosis, investigation and management is essential. Exclusive enteral nutrition is the first line treatment for active disease. The vast majority of children will need immunosuppressant treatment and around 20% will need treatment with biologics. Recent guidelines have helped make best use of available therapies.

scholarly journals CRITICAL ANALYSIS OF ANTI-TNF USE IN THE ERA OF NEW BIOLOGICAL AGENTS IN INFLAMMATORY BOWEL DISEASE

2020 ◽  
Vol 57 (3) ◽  
pp. 323-332 ◽  
Author(s):  
Camila Cunha Gonzaga LIMA ◽  
Natália Sousa Freitas QUEIROZ ◽  
Carlos Walter SOBRADO ◽  
Gustavo Luís Rodela SILVA ◽  
Sérgio Carlos NAHAS
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Bowel Disease ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Long Term Treatment ◽  
Inflammatory Bowel

ABSTRACT BACKGROUND: Inflammatory bowel diseases (IBD), both Crohn’s disease and ulcerative colitis, are chronic immune-mediated diseases that present a relapsing and remitting course and requires long-term treatment. Anti-tumor necrosis factor (anti-TNF) therapy has changed the management of the disease by reducing the need for hospitalizations, surgeries and improving patient´s quality of life. OBJECTIVE: The aim of this review is to discuss the role of anti-TNF agents in IBD, highlighting the situations where its use as first-line therapy would be appropriate. METHODS: Narrative review summarizing the best available evidence on the topic based on searches in databases such as MedLine and PubMed up to April 2020 using the following keywords: “inflammatory bowel disease’’, “anti-TNF agents” and ‘’biologic therapy’’. CONCLUSION: Biological therapy remains the cornerstone in the treatment of IBD. In the absence of head-to-head comparisons, the choice of the biological agent may be challenging and should take into account several variables. Anti-TNF agents should be considered as first line therapy in specific scenarios such as acute severe ulcerative colitis, fistulizing Crohn’s disease and extra-intestinal manifestations of IBD, given the strong body of evidence supporting its efficacy and safety in these situations.

Sign in / Sign up

Export Citation Format

Share Document